Magnetic resonance spectroscopy of the cervical cord in amyotrophic lateral sclerosis

References

• Sarchielli P, Pelliccioli GP, Tarducci R, Chiarini P, Presciutti O, Gobbi G, . Magnetic resonance imaging and 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis. Neuroradiology. 2001;43:189–97.
   PubMed Web of Science ®Google Scholar
• Schuff N, Rooney WD, Miller R, Gelinas DF, Amend DL, Maudsley AA, . Reanalysis of multislice (1)H MRSI in amyotrophic lateral sclerosis. Magn Reson Med. 2001;45: 513–6.
   PubMed Web of Science ®Google Scholar
• Abe K, Takanashi M, Watanabe Y, Tanaka H, Fujita N, Hirabuki N, . Decrease in N-acetylaspartate/creatine ratio in the motor area and the frontal lobe in amyotrophic lateral sclerosis. Neuroradiology. 2001;43:537–41.
   PubMed Web of Science ®Google Scholar
• Chan S, Shungu DC, Douglas-Akinwande A, Lange DJ, Rowland LP. Motor neuron diseases: comparison of single-voxel proton MR spectroscopy of the motor cortex with MR imaging of the brain. Radiology. 1999;212:763–9.
   PubMed Web of Science ®Google Scholar
• Cwik VA, Hanstock CC, Allen PS, Martin WR. Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy. Neurology. 1998;50:72–7.
   PubMed Web of Science ®Google Scholar
• Kalra S, Cashman NR, Caramanos Z, Genge A, Arnold DL. Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. AJNR Am J Neuroradiol. 2003;24:476–80.
   PubMed Web of Science ®Google Scholar
• Pioro EP, Antel JP, Cashman NR, Arnold DL. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology. 1994;44:1933–8.
   PubMed Web of Science ®Google Scholar
• Rule RR, Suhy J, Schuff N, Gelinas DF, Miller RG, Weiner MW. Reduced NAA in motor and non-motor brain regions in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:141–9.
   PubMed Web of Science ®Google Scholar
• Suhy J, Miller RG, Rule R, Schuff N, Licht J, Dronsky V, . Early detection and longitudinal changes in amyotrophic lateral sclerosis by (1)H MRSI. Neurology. 2002;58: 773–9.
   PubMed Web of Science ®Google Scholar
• Kalra S, Cashman NR, Genge A, Arnold DL. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. NeuroReport. 1998;9:1757–61.
   PubMed Web of Science ®Google Scholar
• Block W, Karitzky J, Traber F, Pohl C, Keller E, Mundegar RR, . Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. Arch Neurol. 1998;55:931–6.
   PubMedGoogle Scholar
• Jones AP, Gunawardena WJ, Coutinho CM, Gatt JA, Shaw IC, Mitchell JD. Preliminary results of proton magnetic resonance spectroscopy in motor neuron disease (amytrophic lateral sclerosis). J Neurol Sci. 1995;129 (Suppl):85–9.
   PubMedGoogle Scholar
• Rooney WD, Miller RG, Gelinas D, Schuff N, Maudsley AA, Weiner MW. Decreased N-acetylaspartate in motor cortex and corticospinal tract in ALS. Neurology. 1998;50:1800–5.
   PubMed Web of Science ®Google Scholar
• Kalra S, Hanstock CC, Martin WRW, Allen PS, Johnston WS. Detection of cerebral degeneration in amyotrophic lateral sclerosis using high-field magnetic resonance spectroscopy. Arch Neurol. 2006;63:1144–8.
   PubMedGoogle Scholar
• Bradley WG, Bowen BC, Pattany PM, Rotta F. 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis. J Neurol Sci. 1999;169:84–6.
   PubMed Web of Science ®Google Scholar
• Gredal O, Rosenbaum S, Topp S, Karlsborg M, Strange P, Werdelin L. Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy. Neurology. 1997;48:878–81.
   PubMed Web of Science ®Google Scholar
• Pioro EP, Majors AW, Mitsumoto H, Nelson DR, Ng TC. 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurology. 1999;53: 71–9.
   PubMed Web of Science ®Google Scholar
• Hanstock CC, Cwik VA, Martin WR. Reduction in metabolite transverse relaxation times in amyotrophic lateral sclerosis. J Neurol Sci. 2002;198:37–41.
   PubMed Web of Science ®Google Scholar
• Ellis CM, Simmons A, Andrews C, Dawson JM, Williams SC, Leigh PN. A proton magnetic resonance spectroscopic study in ALS: correlation with clinical findings. Neurology. 1998;51:1104–9.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Pineda-Alonso N, Benatar M, Smith R, Hu X, Carew JD. Reliability of MRS of the cervical spine at 3T. Proc Intl Soc Mag Reson Med. 2008;16:2287.
   Google Scholar
• Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001;14:260–4.
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B. 1995;57:289–300.
   Web of Science ®Google Scholar
• Unrath A, Ludolph AC, Kassubek J. Brain metabolites in definite amyotrophic lateral sclerosis. A longitudinal proton magnetic resonance spectroscopy study. J Neurol. 2007;254:1099–106.
   PubMed Web of Science ®Google Scholar
• Kim JP, Lentz MR, Westmoreland SV, Greco JB, Ratai EM, Halpern E, . Relationships between astrogliosis and 1H MR spectroscopic measures of brain choline/creatine and myo-inositol/creatine in a primate model. AJNR Am J Neuroradiol. 2005;26:752–9.
   Google Scholar